Poster

Long-Term Safety of Once-Nightly Sodium Oxybate for Narcolepsy: RESTORE Study Interim Analysis of Data

The ongoing RESTORE trial is an open-label/switch study evaluating the safety and tolerability of a once-at-bedtime oxybate (ON-SXB). Interim data from RESTORE suggest that the safety pro...

Thomas Stern , MD;

10/26/2023

Left Frontal lobe Meningioma masquerading as Schizophrenia

Frontal lobe tumors are known to alter whole personality, not just memory and retention. They are not easily suspected and missed in patients diagnosed with a psychiatric disorder. We pre...

Rohit Madan , MD;

10/26/2023

Investigating Care Models to Support Older Adults with Depression and Health Comorbidities

An online survey of older adults living with depression and health comorbidities and their care-partners (n = 571; 73.4 % patients and 14.0% peers) was undertaken to identify treatment pr...

Rebecca A. Dickinson , BSc, BA;

10/26/2023

Is It Their Eyes? - Could Your Patients' Psych Symptoms be Due to Binocular Vision Disorder?

This poster shares basic information on BVD - signs, symptoms, causes, screening tools, to educate those in the position of psychiatric evaluation on a potential non-psychiatric etiology ...

Jenna Shock , MSN-ED, APRN, PMHNP-BC;

10/26/2023

Key Characteristics of the Long-Acting Injectable Atypical Antipsychotic Aripiprazole Lauroxil for the Treatment of Adults with Schizophrenia

Aripiprazole lauroxil and its 1-day initiation formulation were specifically developed using an innovative prodrug technology to provide long-acting injectable formulations of aripiprazol...

James A. McGrory , PhD;

10/26/2023

Key Characteristics of the Long-Acting Injectable Atypical Antipsychotic Aripiprazole Lauroxil for the Treatment of Adults with Schizophrenia

Aripiprazole lauroxil and its 1-day initiation formulation were specifically developed using an innovative prodrug technology to provide long-acting injectable formulations of aripiprazol...

Andrew J. Cutler , MD;

10/26/2023

Improvements in Depressive Symptoms in Patients With Major Depressive Disorder: Analysis of Zuranolone Efficacy From 4 Randomized, Placebo-Controlled Trials

An analysis of 4 randomized, placebo-controlled trials evaluating a 14-day treatment course of zuranolone 30- or 50-mg in adults with MDD showed nominally significant improvements (p ...

Anita H. Clayton , MD;

10/26/2023

Incidence and Characteristics of Akathisia With Adjunctive Cariprazine Treatment in Patients With Major Depressive Disorder

Incidence of akathisia was higher for cariprazine than placebo, with lower incidence observed for patients treated with cariprazine 1.5mg/d+ADT versus 3mg/d+ADT, suggesting dose related e...

Majid Kerolous , PharmD, MPH;

10/26/2023

Introducing S.C.O.P.E.™: Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement—An Interactive Digital Platform to Educate on Schizophrenia Care

Educational initiatives targeting common clinical dilemmas encountered by clinicians managing patients with schizophrenia may clarify appropriate use of long-acting injectable antipsychot...

Kelli R. Franzenburg , PhD;

10/26/2023

Impact of Treatment With TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA), at Different Stages of Schizophrenia: a Post Hoc Analysis

TV-46000 is an FDA-approved long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone that has been shown to reduce time to impending relapse in patients with schizophreni...

Kelli R. Franzenburg , PhD;

10/26/2023